CompletedPhase 4

Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause

Denmark10,011 participantsStarted 2023-01-27

Plain-language summary

To examine, among once-daily LAMA using COPD patients, whether evening administration of LAMA is superior with respect to the incidence of hospitalization requiring AECOPD or death from all causes than the more conventional morning administration.

Who can participate

Age range30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age more than or equal to 30 years
✓. Current treatment with LAMA once daily (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire)
✓. Self-reported COPD

What they're measuring

COPD-related hospitalization-requiring (severe) exacerbations

Timeframe: 12 months from randomization

All-cause mortality

Timeframe: 12 months from randomization

Trial details

NCT IDNCT05563675

SponsorChronic Obstructive Pulmonary Disease Trial Network, Denmark

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More COPD Exacerbation trials